Is Supernus a profitable company?
Evaluating the profitability profile of Supernus Pharmaceuticals involves analyzing fluctuating quarterly earnings reports, research and development expenditures, and commercial product sales revenue. While the enterprise generates substantial top-line revenue from its core neurology product lines and maintains healthy gross margins, periodic swings into net losses occur due to strategic investments in clinical pipeline expansion, legal expenses, and commercialization costs associated with new drug launches.
Related FAQs
Supernus Pharmaceuticals operates in rigorous compliance with federal and international pharmaceutical regulations, medical ethics standards, and corporate compliance frameworks.
Supernus Pharmaceuticals specializes in developing and commercializing specialized central nervous system medications designed to treat psychiatric and neurological disorders.
Swire Properties Limited is a major premier developer, owner, and operator of mixed-use commercial and residential properties, primarily centered in Hong Kong and the Chinese mainland.
Supernus Pharmaceuticals operates primarily as a specialty pharmaceutical enterprise rather than a traditional early-stage biotechnology research firm.
The five-two-one rule or similar numerical clinical heuristics for Parkinson's disease assist neurologists and patients in monitoring progressive symptom management, medication timing schedules, and multidisciplinary therapy interventions.
"Swig" is not a widely recognized publicly traded stock ticker, though it is commonly confused with "Swiggy," a major consumer technology company based in India.
Supernus Pharmaceuticals is an authentic, publicly traded corporate entity listed on the Nasdaq Global Select Market under the ticker symbol SUPN.
A 70-year-old individual diagnosed with stage 3 chronic kidney disease can often live a normal lifespan, provided the condition is actively managed and monitored through proper lifestyle modifications, blood pressure control, and dietary adjustmen...
Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals has executed key strategic acquisitions to bolster its neurology and neuropsychiatry product portfolio and diversify its revenue streams.
Supernus Pharmaceuticals maintains a solid reputation within the specialty healthcare and pharmaceutical sector, anchored by its diverse portfolio of FDA-approved medications addressing complex central nervous system disorders.
Yes, Stanley Black & Decker (trading under the ticker SWK) has a long-standing corporate history of executing stock splits throughout its multi-decade trajectory as a premier global industrial tool and hardware manufacturer.
Supernus Pharmaceuticals, Inc. operates as a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.
During the course of Joe Biden's presidency, the stock market experienced strong upward momentum alongside broader macroeconomic shifts, with the Dow Jones Industrial Average rising by roughly 40.
Supernus Pharmaceuticals anticipates a progressive future growth outlook driven by the expansion of its specialized neurology and psychiatry product portfolio, including treatments for epilepsy, attention deficit hyperactivity disorder, and centra...
Supernus Pharmaceuticals operates in the specialty pharmaceutical sector focusing on central nervous system disorders, encountering competition from numerous established drug developers and generic manufacturers.
Levodopa, frequently administered in combination with carbidopa, is universally recognized as the clinical gold standard pharmacological treatment for managing the motor symptoms of Parkinson's disease.
Actor and Parkinson's disease research advocate Michael J.
Supernus Pharmaceuticals, Inc. was officially founded and established in 2005 through a management buyout of specialty pharmaceutical assets from Shire plc.
Supernus Pharmaceuticals, Inc. officially completed its initial public offering and began trading its common stock on the NASDAQ Global Select Market under the ticker symbol SUPN in May 2012.